s6y

Aktis Oncology, Inc.

Ticker
AKTS
CIK
2035832
Industry
Pharmaceutical Preparations

Financials 4

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025

News 6

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing

Ownership 31

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 3 Initial statement of beneficial ownership of securities
  9. 3 Initial statement of beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 31 ownership filings

Prospectus 12

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  3. S-1/A General form of registration statement for all companies including face-amount certificate companies
  4. S-1/A General form of registration statement for all companies including face-amount certificate companies
  5. S-1 General form of registration statement for all companies including face-amount certificate companies
  6. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  7. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  8. DRSLTR Correspondence Related to Draft Registration Statement
  9. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  10. DRSLTR Correspondence Related to Draft Registration Statement

All 12 prospectus filings

Other 19

  1. SCHEDULE 13G
  2. 144 Filing for proposed sale of securities under Rule 144
  3. 144 Filing for proposed sale of securities under Rule 144
  4. 144 Filing for proposed sale of securities under Rule 144
  5. 144 Filing for proposed sale of securities under Rule 144
  6. 144 Filing for proposed sale of securities under Rule 144
  7. SCHEDULE 13G
  8. SCHEDULE 13D
  9. SCHEDULE 13D
  10. SCHEDULE 13D

All 19 other filings